MetaCap

Odyssey Therapeutics (ODTX) vs Prime Medicine (PRME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Odyssey Therapeutics is the larger company by market cap ($815.2 million vs $791.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ODTX+3.29%PRME+10.59%
+80%+30%-20%
May 8, 20261 yearNov 20, 2026
ODTX+3.29%PRME+10.59%
+80%+31%-18%
May 4, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ODTX versus PRME key metrics
MetricODTXPRME
Share price$16.96$3.55
Market cap$815.23M$791.62M
1-day change-7.52%-7.55%
YTD return—+2.31%
1-year return—-2.20%
EPS (TTM)$-6.33$-0.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.63M
Revenue growth (YoY)—+55.28%
Net income (latest FY)—$-201.14M
Operating margin—-4498.06%
Net margin—-4342.44%
52-week high$29.05$5.91
52-week low$15.10$2.67
Distance from 52-week high-41.62%-39.93%
Analyst consensusstrong_buybuy
Avg. price target upside+104.42%+108.17%
Average volume329.31K4.64M
Shares outstanding48.07M222.99M
Employees100146
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Odyssey Therapeutics

ODTX stock →

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees

About Prime Medicine

PRME stock →

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees

ODTX vs PRME FAQ

Which is bigger, Odyssey Therapeutics or Prime Medicine?

Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $815.23M compared with $791.62M for Prime Medicine (PRME).

Are Odyssey Therapeutics and Prime Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons